[ad_1]
Study results revealed improved symptoms and quality of life for patients with musculoskeletal pain and inflammation.
TORONTO, April 10, 2024 (GLOBE NEWSWIRE) — Avicanna Inc.Avicanna” or “company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) Biopharmaceutical company focused on developing, manufacturing and commercializing plant-derived cannabinoid-based products announces completion of real-world observational evidence We are pleased to conduct a study using RHO Phyto brand cannabigerol (“CBG”) transdermal gel (“RWE”) in patients with musculoskeletal pain and inflammation.
The RWE study showed that RHO Phyto-CBG transdermal gel containing 2% cannabidiol (“CBD”) and 1% CBG was used to treat arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, myalgia, joint pain, topical We evaluated the validity of patient reports for various clinical symptoms such as pain. Pain, muscle and structural damage, post-operative pain. Seventy-one participants completed a baseline examination and a 1-month follow-up that included demographics, medical history, drug use, and two standardized symptom questionnaires.
The RWE study revealed a significant improvement (p<0.001) in Global Musculoskeletal Health Questionnaire scores compared to baseline to 1 month. Specifically, 35.4% improvements were reported in health-related areas such as symptoms, physical function, daily activities and work, physical health, and confidence in managing symptoms. Additionally, evaluation of the Edmonton Symptom Assessment System questionnaire also revealed improvement in pain, sleep, anxiety, and well-being symptoms from baseline to 1 month (p<0.001).
“Preliminary results from this study are consistent with reported results for our product in Canadian patients and provide valuable insight into the next stage of clinical development. It will advance legislative initiatives regarding medical marijuana and cosmetics,” said Dr. Carolina Urban, Executive Vice President of Medical Affairs.
All RWE study participants (64% female) with a mean age of 58 ± 15 years had symptoms of chronic pain. According to the ICD-10 diagnostic classification, 21.1% of participants had a diagnosis related to arthritis (polyarthritis, osteoarthritis, etc.), 17.5% of participants had back pain, and 12.3% had fibromyalgia. , 8% were diagnosed with chronic intractable pain. Before the study began, study participants reported taking an average of 10 medications, including NSAIDs, opioids, antidepressants, and skeletal muscle relaxants. Each RWE study participant was assigned a common treatment regimen that combined CBD oil (83.3%) or Balance oil (16.7%) with her RHO PhytoCBG transdermal gel..
About RHO Phyto Transdermal CBG Gel
CBG transdermal gel is part of Avicanna’s RHO Phyto formulation of medical products, which includes proprietary oral, sublingual, and topical products containing various cannabinoids. This gel contains a combination of his CBG and CBD in a highly absorbent water-based gel that is meant to be applied topically to concentrated areas. This gel utilizes Avicanna’s deep tissue emulsion technology, combining natural ingredients that synergize with cannabinoids and terpenes such as menthol, eugenol, and beta-caryophyllene.
About Avicanna Co., Ltd.
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for global medical and pharmaceutical market segments. Avicanna has an established scientific platform that includes research and development and clinical development, leading to the commercialization of over 30 unique evidence-based end products, supporting his four business pillars at the commercial stage. I am.
-
Medical Cannabis Formula (RHO Phyto™): Supported by ongoing patient and medical community education, Formulary offers a variety of proprietary products including oral, sublingual, topical, and transdermal delivery containing varying proportions of cannabinoids. RHO Phyto is Canada’s established leading healthcare brand, currently available to patients through multiple healthcare channels across the country, and continues to expand into new international markets.
-
Medical Cannabis Care Platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed to better meet the needs of medical cannabis patients and enhance their journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse product portfolio and bilingual pharmacist-led patient support program. MyMedi.ca also provides specialized services to distinct patient groups, such as veterans, and works with public and private payers on adjudication and reimbursement. MyMedi.ca provides the medical community with educational resources to facilitate the integration of medical cannabis into health care plans.
-
Pharmaceuticals (Trunerox™) and pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a unique pipeline of indication-specific medicines in various stages of clinical development and commercialization. These cannabinoid-based drug candidates aim to address unmet medical needs in the fields of dermatology, chronic pain, and various neurological diseases. Avicanna’s first indication-specific medicine, Trunerox™, was approved by the Colombian Health Authority INVIMA in the first quarter of 2024 as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
-
Active Pharmaceutical Ingredients (Aureus Santa Marta™): Active Pharmaceutical Ingredients (“APIs”) supplied by our majority-owned subsidiary, Santa Marta Golden Hemp SAS (“SMGH”), provide our international partners with high quality CBD, THC and CBG in a variety of forms. This is a commercial stage business specializing in Used in the development and production of food, cosmetics, medical products, and pharmaceuticals. This business unit is also part of our supply chain and a reliable source of input products for consumer retail, medical cannabis and pharmaceuticals worldwide.
Source Avicanna.
stay connected
For more information about Avicanna, please visit: our websitecontact Ivana Maric by email at info@avicanna.com or follow us on social media. linkedin, twitter, Facebookor Instagram.
We will send out the latest information from our company via video. YouTube channel.
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release refers to forward-looking information that “may,” “will,” “could,” “will,” “likely,” “expected,” and “anticipated.” “will”, “believe”, “intends”, “plans”, “forecasts”, “projects”, “estimates”, “forecasts” and similar expressions. Although the Company believes that the expectations and assumptions underlying such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information as there can be no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated in these statements. Forward-looking information is subject to various risks and uncertainties that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Such risks and uncertainties include current and future market conditions, including the market price of the Company’s common shares, and the risks and uncertainties described in the Company’s Annual Information Form dated April 1, 2024 filed with a Canadian securities firm; These include, but are not limited to, risk factors. Regulators and available from his SEDAR Company Profile at www.sedar.com. The information contained in this news release is current as of the date of this release. The Company disclaims any intention or obligation to update any forward-looking information, whether as a result of new information, future events or results, or otherwise, except as required by applicable securities laws. yeah.
Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fab77b86-bdad-4cda-8307-dba91631e46c.
[ad_2]
Source link
